-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
-
Summary
-
Merrimack Pharmaceuticals Inc quarterly/annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and growth rate from 2010 to 2023.
- Merrimack Pharmaceuticals Inc Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending March 31, 2024 was $201M.
- Merrimack Pharmaceuticals Inc Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the twelve months ending March 31, 2024 was $200M.
- Merrimack Pharmaceuticals Inc annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2023 was -$1.18M, a 23.5% increase from 2022.
- Merrimack Pharmaceuticals Inc annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was -$1.54M, a 37.1% increase from 2021.
- Merrimack Pharmaceuticals Inc annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2021 was -$2.46M, a 18.9% increase from 2020.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Annual (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Annual Growth (%)